Read Time:8 Second
The approval is a win for Merck, which is working to diversify its revenue stream as its blockbuster cancer drug Keytruda nears a loss of market exclusivity.
Happy
0 %
Sad
0 %
Excited
0 %
Sleepy
0 %
Angry
0 %
Surprise
0 %
0
0
